Today

S-1 registers more Class A shares and details insider redemptions.

Crestone files S‑1 for a SPAC; auditor flagged going‑concern and VIE/legal risks.

LiqTech filed an S-1 to register up to $20M, citing going-concern and debt-exchange plans.

S-1 registers up to 6.3M UGRO shares for resale; filing flags liquidity and listing risks.

Eni reports termination of the first tranche and start of the second tranche of its 2026 treasury share buyback program, with reported purchases during 19–22 May 2026 totaling 3,363,076 shares (snippet).

Bleichroeder filed an F-4 registering the Pasqal merger and related warrants and convertible bonds.

Cayson filed an amended F-4 with a proxy/prospectus for a merger vote with Mango.

S-4 registers shares and exhibits for proposed Allegro merger, PIPE and executive agreements.

Nasdaq filed Form 25 to remove GigCapital7 units (GIGGU) from Nasdaq.

Regulation A amendment cuts the offering price to $0.008 per share.

Company filed a registered direct offering with shares, pre-funded warrants and placement-agent warrants.

Embrace Change filed a Form 12b-25 notifying a late 10-Q and outstanding 2025 10-K.

Kanzhun's 6‑K (with Exhibit 99.1) discloses bulk issuance of 647,636 Class A ordinary shares to the ADS depositary reserved for ADS issuance and settlement/vesting of 20,000 RSUs on May 26, 2026 — potential dilution exists but materiality is unclear without market context.

Six-K includes Exhibit 99.1 with 12-month earnings and coverage metrics (e.g., $13,030 million earnings before interest on subordinated indebtedness and income tax; $674 million adjusted amount; subordinated interest requirements $326 million; grossed-up dividend coverage ~62%).

G-III Apparel Group declared a quarterly cash dividend of $0.10 per share, payable July 8, 2026 to holders of record on June 22, 2026 (Exhibit 99.1). Market context (price / shares outstanding) is needed to compute yield and aggregate payout.

Movado reported improving first-quarter fiscal 2027 results (net sales ~$142.4M; operating income $7.0M; diluted EPS $0.30) and the Board approved a quarterly dividend and share repurchase program. Positive operating leverage and margin expansion appear to have driven the EPS recovery; market context and exact capital-return sizing are needed to assess investor impact.

Precision BioSciences reported late-breaker Phase 1 ELIMINATE-B data at EASL claiming a 1-log reduction in cccDNA-derived transcripts and pgRNA loss in all patients with detectable pgRNA (n=6). Results are promising but early and based on small cohorts — further review and market context needed.

Bank of Nova Scotia filed a Form 6-K with exhibits (99.1, 99.2) that include a consolidated capitalization table as at April 30, 2026 (subordinated debentures 5,766; common shares 22,002; retained earnings 59,876; total common equity 77,222; preferred shares and other equity instruments 9,939). The filing notes IFRS 17 adoption; full income/stated-period earnings metrics are not extracted in the wrapper — analyst review recommended.

Monro (MNRO) announced a formal review of strategic alternatives (Exhibit 99.2), furnished Q4/FY26 results (Exhibit 99.1) showing reduced sales and a $6.6M net loss for the quarter, and the board declared a $0.28 quarterly dividend payable June 16, 2026. The strategic review could lead to significant corporate actions; details and market context are needed to assess materiality.

Fusion Fuel (HTOO) filed a 6‑K announcing an EGM on June 8, 2026 to approve the Royal Uranium acquisition, conversion of 4,171,327 preferred shares into ordinary shares, and a proposed name change; the board recommends voting FOR. Key transaction economics and pro‑forma share counts are not provided in the filing.